
EquityIndex FundsVery High Risk
Direct
NAV (18-Feb-26)
Returns (Since Inception)
Fund Size
₹16 Cr
Expense Ratio
0.65%
ISIN
INF194KB1IS2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
22 Oct 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+7.95%
— (Cat Avg.)
Since Inception
+0.69%
— (Cat Avg.)
| Equity | ₹15.75 Cr | 100.19% |
| Others | ₹-0.03 Cr | -0.19% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹2.08 Cr | 13.21% |
| Divi's Laboratories Ltd | Equity | ₹0.95 Cr | 6.05% |
| Cipla Ltd | Equity | ₹0.92 Cr | 5.87% |
| Dr Reddy's Laboratories Ltd | Equity | ₹0.92 Cr | 5.82% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹0.88 Cr | 5.57% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹0.87 Cr | 5.55% |
| Lupin Ltd | Equity | ₹0.64 Cr | 4.08% |
| Fortis Healthcare Ltd | Equity | ₹0.55 Cr | 3.48% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.51 Cr | 3.26% |
| Laurus Labs Ltd | Equity | ₹0.46 Cr | 2.94% |
| Aurobindo Pharma Ltd | Equity | ₹0.42 Cr | 2.65% |
| Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 2.61% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.37 Cr | 2.37% |
| Mankind Pharma Ltd | Equity | ₹0.29 Cr | 1.86% |
| Zydus Lifesciences Ltd | Equity | ₹0.27 Cr | 1.75% |
| Biocon Ltd | Equity | ₹0.27 Cr | 1.73% |
| Ipca Laboratories Ltd | Equity | ₹0.25 Cr | 1.61% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.19 Cr | 1.19% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.18 Cr | 1.17% |
| Abbott India Ltd | Equity | ₹0.18 Cr | 1.14% |
| Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.14% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.16 Cr | 1.01% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.15 Cr | 0.93% |
| Ajanta Pharma Ltd | Equity | ₹0.15 Cr | 0.93% |
| Wockhardt Ltd | Equity | ₹0.14 Cr | 0.90% |
| Sai Life Sciences Ltd | Equity | ₹0.14 Cr | 0.89% |
| Neuland Laboratories Ltd | Equity | ₹0.14 Cr | 0.89% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.13 Cr | 0.85% |
| Acutaas Chemicals Ltd | Equity | ₹0.12 Cr | 0.77% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.12 Cr | 0.76% |
| Piramal Pharma Ltd | Equity | ₹0.12 Cr | 0.74% |
| Syngene International Ltd | Equity | ₹0.11 Cr | 0.70% |
| Global Health Ltd | Equity | ₹0.11 Cr | 0.69% |
| Granules India Ltd | Equity | ₹0.1 Cr | 0.65% |
| Jubilant Pharmova Ltd | Equity | ₹0.1 Cr | 0.61% |
| Natco Pharma Ltd | Equity | ₹0.09 Cr | 0.59% |
| Pfizer Ltd | Equity | ₹0.08 Cr | 0.54% |
| OneSource Specialty Pharma Ltd | Equity | ₹0.08 Cr | 0.50% |
| Cohance Lifesciences Ltd | Equity | ₹0.08 Cr | 0.48% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹0.07 Cr | 0.48% |
| Poly Medicure Ltd | Equity | ₹0.07 Cr | 0.46% |
| Strides Pharma Science Ltd | Equity | ₹0.07 Cr | 0.46% |
| Net Current Assets | Cash | ₹-0.07 Cr | 0.45% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.07 Cr | 0.44% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.07 Cr | 0.44% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.07 Cr | 0.42% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.06 Cr | 0.39% |
| Indegene Ltd | Equity | ₹0.06 Cr | 0.39% |
| Metropolis Healthcare Ltd | Equity | ₹0.06 Cr | 0.38% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.06 Cr | 0.36% |
| Emcure Pharmaceuticals Ltd | Equity | ₹0.05 Cr | 0.35% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.05 Cr | 0.34% |
| Procter & Gamble Health Ltd | Equity | ₹0.05 Cr | 0.33% |
| Concord Biotech Ltd | Equity | ₹0.05 Cr | 0.31% |
| Aarti Pharmalabs Ltd | Equity | ₹0.05 Cr | 0.30% |
| Sanofi India Ltd | Equity | ₹0.04 Cr | 0.28% |
| Caplin Point Laboratories Ltd | Equity | ₹0.04 Cr | 0.28% |
| Marksans Pharma Ltd | Equity | ₹0.04 Cr | 0.27% |
| Triparty Repo Trp_020226_val | Cash - Repurchase Agreement | ₹0.04 Cr | 0.25% |
| Shilpa Medicare Ltd | Equity | ₹0.04 Cr | 0.24% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.04 Cr | 0.24% |
| Alivus Life Sciences Ltd | Equity | ₹0.04 Cr | 0.23% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹0.04 Cr | 0.22% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.20% |
| Viyash Scientific Ltd | Equity | ₹0.03 Cr | 0.19% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.03 Cr | 0.17% |
| Senores Pharmaceuticals Ltd | Equity | ₹0.03 Cr | 0.17% |
| Thyrocare Technologies Ltd | Equity | ₹0.02 Cr | 0.15% |
| FDC Ltd | Equity | ₹0.02 Cr | 0.14% |
| Supriya Lifescience Ltd | Equity | ₹0.02 Cr | 0.14% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.02 Cr | 0.13% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.11% |
| Blue Jet Healthcare Ltd | Equity | ₹0.02 Cr | 0.11% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.11% |
| Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.11% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.10% |
| Morepen Laboratories Ltd | Equity | ₹0.02 Cr | 0.10% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.01 Cr | 0.09% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.09% |
| Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.09% |
| Innova Captab Ltd | Equity | ₹0.01 Cr | 0.09% |
| Orchid Pharma Ltd | Equity | ₹0.01 Cr | 0.08% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.08% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
| 3B BlackBio Dx Ltd | Equity | ₹0.01 Cr | 0.06% |
| Gufic Biosciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
| Indoco Remedies Ltd | Equity | ₹0.01 Cr | 0.06% |
| Unichem Laboratories Ltd | Equity | ₹0.01 Cr | 0.06% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.06% |
| Hikal Ltd | Equity | ₹0.01 Cr | 0.06% |
| Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.05% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.05% |
| Panacea Biotec Ltd | Equity | ₹0.01 Cr | 0.05% |
| Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.05% |
| Dr Agarwal'S Eye Hospital Ltd | Equity | ₹0.01 Cr | 0.04% |
| Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.04% |
| Suraksha Diagnostic Ltd | Equity | ₹0.01 Cr | 0.04% |
| Fischer Medical Ventures Ltd | Equity | ₹0.01 Cr | 0.04% |
| Novartis India Ltd | Equity | ₹0.01 Cr | 0.04% |
| Kwality Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.04% |
| Bajaj Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.04% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.03% |
| Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.03% |
| Wanbury Ltd | Equity | ₹0.01 Cr | 0.03% |
| Laxmi Dental Ltd | Equity | ₹0 Cr | 0.03% |
| GPT Healthcare Ltd | Equity | ₹0 Cr | 0.03% |
| Kopran Ltd | Equity | ₹0 Cr | 0.03% |
| Fermenta Biotech Ltd | Equity | ₹0 Cr | 0.03% |
| Jagsonpal Pharmaceuticals Ltd | Equity | ₹0 Cr | 0.02% |
| Tarsons Products Ltd | Equity | ₹0 Cr | 0.02% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
| Themis Medicare Ltd | Equity | ₹0 Cr | 0.02% |
| Anuh Pharma Ltd Shs Dematerialised | Equity | ₹0 Cr | 0.02% |
| Nectar Lifesciences Ltd | Equity | ₹0 Cr | 0.01% |
| Shree Ganesh Remedies Ltd Ordinary Shares | Equity | ₹0 Cr | 0.01% |
| Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Large Cap Stocks
45.33%
Mid Cap Stocks
28.60%
Small Cap Stocks
26.27%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹15.61 Cr | 99.31% |
| Basic Materials | ₹0.14 Cr | 0.88% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since March 2025
ISIN INF194KB1IS2 | Expense Ratio 0.65% | Exit Load No Charges | Fund Size ₹16 Cr | Age 1 year 3 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹1,95,394 Cr
Address
6th Floor, 841, One World Center, Mumbai, 400013
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments